Similar articles

• Pharmacological studies with an alkylating narcotic agonist, chloroxymorphamine, and antagonist, chlornaltrexamine.

  Caruso TP, Larson DL, Portoghese PS, Takemori AE. Caruso TP, et al. J Pharmacol Exp Ther. 1980 Jun;213(3):539-44. J Pharmacol Exp Ther. 1980. PMID: 6162947
• Chloroxymorphamine, and opioid receptor site-directed alkylating agent having narcotic agonist activity.

  Caruso TP, Takemori AE, Larson DL, Portoghese PS. Caruso TP, et al. Science. 1979 Apr 20;204(4390):316-8. doi: 10.1126/science.86208. Science. 1979. PMID: 86208
• Irreversible opiate agonists and antagonists. II. Evidence against a bivalent mechanism of action for opiate azines and diacylhydrazones.

  Hahn EF, Nishimura S, Goodman RR, Pasternak GW. Hahn EF, et al. J Pharmacol Exp Ther. 1985 Dec;235(3):839-45. J Pharmacol Exp Ther. 1985. PMID: 2416909
• Pharmacologic management of patients undergoing conscious sedation.

  Goodwin SA. Goodwin SA. Clin Nurse Spec. 2001 Nov;15(6):269-71. doi: 10.1097/00002800-200111000-00008. Clin Nurse Spec. 2001. PMID: 11855482 Review. No abstract available.
• Preclinical toxicity studies of naltrexone.

  Braude MC, Morrison JM. Braude MC, et al. NIDA Res Monogr. 1976 Sep;(9):16-26. doi: 10.1037/e497452006-006. NIDA Res Monogr. 1976. PMID: 826824 Review. No abstract available.